CA-CHUGAI-PHARMACEUTICAL
4.12.2018 02:02:07 CET | Business Wire | Press release
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that the primary analysis of the phase III HAVEN 2 study (NCT02795767), evaluating hemophilia A treatment HEMLIBRA® [generic name: emicizumab (genetical recombination)] in children with hemophilia A with factor VIII inhibitors, was reported in an Oral Presentation at the 60th American Society of Hematology (ASH) Annual Meeting held in San Diego, USA from December 1 to 4 2018. These data, including longer follow-up (median of 11 additional months of data for once weekly dosing) and new data for less frequent dosing schedules (every two weeks or every four weeks), demonstrated clinically meaningful control of bleeding.
“Bleeding control is important especially for children with hemophilia A. I am happy that HEMLIBRA showed positive data from a longer period of treatment in children younger than 12 years of age with hemophilia A with inhibitors,” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Yasushi Ito. “HEMLIBRA has been approved in more than 50 countries. I hope that the new data will broaden the potential contribution of HEMLIBRA in people with hemophilia A with inhibitors who have limited treatment options.”
HAVEN 2 Study
Study description
The HAVEN 2 study is a multicenter, open-label, clinical phase III study evaluating the efficacy, safety and pharmacokinetics of once weekly, every two weeks or every four weeks subcutaneous administration of HEMLIBRA prophylaxis in children younger than 12 years of age with hemophilia A with factor VIII inhibitors. The primary analysis on evaluation of efficacy included 85 children (once weekly dosing, Arm A, n=65; every two weeks dosing, Arm B, n=10; every four weeks dosing, Arm C, n=10) with hemophilia A with factor VIII inhibitors. The median follow-up period of Arm A, B and C was 58 (range 17.9–92.6), 21.3 (range 18.6–24.1), and 19.9 (range 8.9–24.1) weeks, respectively.
Study design n=85
- HEMLIBRA prophylaxis was administered as follows.
|
Arm A |
Received HEMLIBRA prophylaxis at 3 mg/kg by once-weekly subcutaneous injection for 4 weeks, followed by 1.5 mg/kg once-weekly subcutaneous injection | |
|
Arm B |
Received HEMLIBRA prophylaxis at 3 mg/kg by once-weekly subcutaneous injection for 4 weeks, followed by 3 mg/kg once every two weeks subcutaneous injection | |
|
Arm C |
Received HEMLIBRA prophylaxis at 3 mg/kg by once-weekly subcutaneous injection for 4 weeks, followed by 6 mg/kg once every four weeks subcutaneous injection | |
- The prospective intra-patient comparison included 18 patients from the once weekly cohort (Arm A) previously treated with bypassing agents (BPAs) either as prophylaxis (n=15) or on-demand (n=3) as part of a non-interventional study.
|
Summary of results |
||||
| Arm A | ||||
| Annualized bleeding rate [ABR] (95% CI) | Median ABR (Interquartile range; IQR) | |||
| Treated bleeds (primary endpoint) |
0.3
(0.17; 0.50) |
0.0
(0.00; 0.00) |
||
| All bleeds |
3.2
(1.94; 5.22) |
0.6
(0.00; 2.92) |
||
| Treated spontaneous bleeds |
0.0
(0.01; 0.10) |
0.0
(0.00; 0.00) |
||
| Treated joint bleeds |
0.2
(0.08; 0.29) |
0.0
(0.00; 0.00) |
||
| Treated target joint bleeds | Not estimable |
0.0
(0.00; 0.00) |
||
| Arm B | Arm C | |||
| ABR, treated bleeds (95% CI) |
0.2
(0.03; 1.72) |
2.2
(0.69; 6.81) |
||
| Median ABR, treated bleeds (IQR) |
0.0
(0.00; 0.00) |
0.0
(0.00; 3.26) |
||
|
% patients with zero treated bleeds
(95% CI) |
90.0%
(55.5; 99.7) |
60.0%
(26.2; 87.8) |
||
|
% patients with 1-3 treated bleeds
(95% CI) |
10.0%
(0.3; 44.5) |
40.0%
(12.2; 73.8) |
||
- In patients receiving HEMLIBRA once weekly (Arm A), 76.9% (95% CI, 64.8; 86.5) experienced zero treated bleeds and 23.1% experienced 1–3 treated bleeds.
- Once-weekly HEMLIBRA dosing showed a 99% (95% CI: 97.7 - 99.4) reduction in treated bleeds compared to prior treatment with bypassing agents (BPAs) as prophylaxis (n=15) or on-demand (n=3) in a prospective intra-patient comparison in Arm A.
- The most common adverse reactions occurring in 10% or more of children treated with HEMLIBRA were common cold symptoms (nasopharyngitis; 37.5%), injection site reactions (29.5%), fever (pyrexia; 23.9%), upper respiratory tract infection (23.9%), cough (23.9%), diarrhoea (15.9%), vomiting (15.9%), headache (14.8%), contusion (12.5%), fall (12.5%) and influenza (10.2%).
- No cases of thrombotic microangiopathy (TMA) or thrombotic events occurred.
- Four patients tested positive for anti-drug antibodies (ADAs) to HEMLIBRA. Of these patients, two had ADAs with neutralizing potential based on reduced HEMLIBRA levels. As previously reported, the ADA in one of these patients resulted in reduced efficacy of HEMLIBRA and led to discontinuation of treatment. The other patient had no bleeds as of the clinical cut-off date of the study.
Also, the data from HOHOEMI study (JapicCTI-173710) were reported as a Poster Presentation at the ASH Annual Meeting. The HOHOEMI study is conducted in Japan by Chugai to investigate the efficacy, safety and pharmacokinetics of every two weeks or every four weeks subcutaneous administration of HEMLIBRA prophylaxis in children younger than 12 years of age with hemophilia A without inhibitors including pediatric patients previously untreated with FVIII.
About Chugai
Chugai Pharmaceutical is one of Japan’s leading research-based
pharmaceutical companies with strengths in biotechnology products.
Chugai, based in Tokyo, specializes in prescription pharmaceuticals and
is listed on the 1st section of the Tokyo Stock Exchange. As an
important member of the Roche Group, Chugai is actively involved in R&D
activities in Japan and abroad. Specifically, Chugai is working to
develop innovative products which may satisfy the unmet medical needs,
mainly focusing on the oncology area.
In Japan, Chugai’s research
facilities in Gotemba and Kamakura are collaborating to develop new
pharmaceuticals and laboratories in Ukima are conducting research for
technology development for industrial production. Overseas, Chugai
Pharmabody Research
based in Singapore is engaged in research
focusing on the generation of novel antibody drugs by utilizing Chugai’s
proprietary innovative antibody engineering technologies. Chugai
Pharma USA
and Chugai
Pharma Europe
are engaged in clinical development activities in the
United States and Europe.
The consolidated revenue in 2017 of
Chugai totalled 534.2 billion yen and the operating income was 103.2
billion yen (IFRS Core basis).
Additional information is available
on the internet at https://www.chugai-pharm.co.jp/english
.
Trademarks used or mentioned in this release are protected by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181203006058/en/
Contact:
For Media Chugai Pharmaceutical Co., Ltd. Media Relations Group, Corporate Communications Dept., Tomoko Shimizu Tel: +81-3-3273-0881 E-mail: pr@chugai-pharm.co.jp
For US media Chugai Pharma USA Inc. Casey Astringer Tel: +1-908-516-1350 E-mail: pr@chugai-pharm.com
For European media Chugai Pharma France SAS Nathalie Leroy Tel: +33-1-56-37-05-21 E-mail: pr@chugai.eu
For Taiwanese media Chugai Pharma Taiwan Ltd. Susan Chou Tel: +886-2-2715-2000 E-mail: pr@chugai.com.tw
For Investors Chugai Pharmaceutical Co., Ltd. Investor Relations Group, Corporate Communications Dept., Toshiya Sasai Tel: +81-3-3273-0554 E-mail: ir@chugai-pharm.co.jp
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 16:24:00 CET | Press release
Refreshed framework reflects today’s technology landscape with streamlined design guidance, refreshed objectives and three levels of organizational assessment When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technolo
North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 16:04:00 CET | Press release
Microsoft-backed Saskatchewan project developed by MLTC and Svante among only three BECCS projects selected North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioene
Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 15:32:00 CET | Press release
Developers Can Now Reach Players on Desktop and the Web With Xsolla Player and Xsolla Pages Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally req
From London 1851 to Riyadh 2030: The United Kingdom Continues Its World Expo Legacy with the Signing of Its Participation Contract for Expo 2030 Riyadh19.11.2026 15:10:00 CET | Press release
The United Kingdom has signed its Participation Contract for Expo 2030 Riyadh, confirming its place at one of the world’s largest global gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119617914/en/ The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State for Foreign Affairs, Climate Envoy, and Commissioner General of Expo 2030 Riyadh; and Lord Sarwar, UK Minister for Trade; and Talal Al-Marri, CEO of Expo 2030 Riyadh. The Agreement constitutes a significant milestone in the United Kingdom’s journey towards Expo 2030 Riyadh, establishing the framework for the execution of its pavilion, programming and visitor experience. This latest agreement adds to a growing number of Participation Contract signings, reflecting increasing momentum behind Expo 2030 Riyadh and the value countries are placing on being part of it. The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State
Rimini Street to Host Investor Day on January 14, 2027, in New York City19.11.2026 15:00:00 CET | Press release
The Company will highlight its opportunities and unique solutions in enterprise software support and its ownership of the Agentic AI ERP market, present its sales strategy and financial model and host a panel discussion featuring Rimini Street global clients from a variety of industries Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced details for its upcoming Investor Day, to be held on January 14, 2027, in New York City. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119878624/en/ Rimini Street to Host Investor Day on January 14, 2027, in New York City Investor Day Details Date: January 14, 2027 Time: 8:30 a.m. – 12:30 p.m. Eastern Time Location: New York City In-Person Attendance: Institutional investors and analysts in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
